GlassScriptPhysician profile
Calprunia James
NPI 1376199083
$1,098.87
in general payments reported to CMS, 2019-2025
17 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $377 · 2022: $256 · 2023: $60.53 · 2024: $136 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $241.94 | 2024-2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $100.24 | 2022 | |
| Esperion Therapeutics, INC. | $99.42 | 2021 | |
| Incyte Corporation | $92.86 | 2021 | |
| Akebia Therapeutics INC | $91.51 | 2025 | Vafseo |
| Xeris Pharmaceuticals, INC. | $84.21 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $71.96 | 2021 | |
| Fresenius USA Marketing, INC. | $71.93 | 2022 | |
| Novo Nordisk INC | $50.16 | 2021-2025 | Ozempic |
| Medtronic, INC. | $39.14 | 2023 | Corevalve Evolut R |
| Abbvie INC. | $28.13 | 2021 | |
| Janssen Scientific Affairs, LLC | $25.02 | 2025 | Invega Sustenna |
| Janssen Pharmaceuticals, INC | $24.25 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.39 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.04 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.96 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calprunia James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.